Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Free Cash Flow: 2014-2025

Historic Free Cash Flow for Zevra Therapeutics (ZVRA) over the last 10 years, with Sep 2025 value amounting to $4.2 million.

  • Zevra Therapeutics' Free Cash Flow rose 122.90% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.2 million, marking a year-over-year increase of 65.21%. This contributed to the annual value of -$69.7 million for FY2024, which is 105.92% down from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Free Cash Flow is $4.2 million, which was up 208.94% from -$3.8 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Free Cash Flow peaked at $16.5 million during Q2 2021, and registered a low of -$19.1 million during Q2 2024.
  • Its 3-year average for Free Cash Flow is -$10.1 million, with a median of -$8.7 million in 2023.
  • As far as peak fluctuations go, Zevra Therapeutics' Free Cash Flow skyrocketed by 652.21% in 2021, and later tumbled by 419.77% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Free Cash Flow (Quarterly) stood at -$865,000 in 2021, then plummeted by 419.77% to -$4.5 million in 2022, then crashed by 260.99% to -$16.2 million in 2023, then declined by 0.12% to -$16.2 million in 2024, then soared by 122.90% to $4.2 million in 2025.
  • Its Free Cash Flow was $4.2 million in Q3 2025, compared to -$3.8 million in Q2 2025 and -$8.3 million in Q1 2025.